Journal
ANTIVIRAL RESEARCH
Volume 178, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.antiviral.2020.104787
Keywords
-
Categories
Funding
- National Breast Cancer Foundation Fellowship, Australia [ECF-17-007]
- National Health and Medical Research Council (NHMRC), Australia [APP1103050]
Ask authors/readers for more resources
Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect -5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available